Treatment with atorvastatin is prescribed at a dose of 80 mg / day from the first 24-96 hours of AMI in addition to the standard therapy.
If there is no achievement of the target level of LDL-C, ≤1.5 mmol / L after 5-6 weeks from the AMI onset, patients additionally receive ezetimibe at a dose of 10 mg 1 time / day.

Myocardial Infarction, Acute

Myocardial Strain

Arterial Stiffness

Quality of Life

Atorvastatin is prescribed at a dose of 80 mg / day from the first 24-96 hours of AMI in addition to the standard therapy

Atorvastatin 80mg

Valentin Oleynikov

Assessment of the Effects of Long-term Lipid-lowering Therapy in Patients With Primary STEMI or NSTEMI

Assessment of the Effects of Long-term Lipid-lowering Therapy on Parameters of Electrical Myocardial Heterogeneity, Myocardial Deformation Characteristics, Vascular Rigidity, and Quality of Life in Patients With Primary STEMI or NSTEMI

Statistically significant differences in the frequency of ventricular arrhythmias as compared to controls

Statistically significant differences in systolic function of the left ventricle according to transthoracic echocardiography as compared to controls;

Statistically significant differences in the myocardial deformation of the LA and LV as compared to controls

Statistically significant differences for major coronary events - PCI / CABG for a new case of coronary atherosclerosis, hospitalization for unstable angina as compared to controls

Statistically significant differences in the late ventricular potentials, heart rate variability, QT interval dispersion (ms) as compared to controls

Statistically significant differences in the parameters of heart rate turbulence (%) as compared to controls

Statistically significant differences for incidence of CV events as compared to controls

Statistically significant differences in the frequency of repeated fatal / non-fatal MI as compared to controls

Statistically significant differences according to the frequency of hospitalization due to acute decompensation of heart failure as compared to controls

Statistically significant differences in pulse wave velocities in arteries of various calibers, as compared to controls

Statistically significant differences in intima-media thickness of carotid artery according ultrasound, as compared to controls

Statistically significant differences in flow-mediated dilation parameters (diameter of brachial artery, mm) assessed by ultrasound, as compared to controls

Statistically significant differences in 6-minute walk test (distance covered, m), as compared to controls

Statistically significant differences in BNP level (pg/ml), as compared to controls

Statistically significant differences echocardiographic parameters of left ventricle pathological remodeling (ejection fraction, %, EDVi, ESVi) as compared to controls

Statistically significant differences of lipid profile (mmol/l) as compared to controls

Statistically significant differences of CRP (mg/l) as compared to controls

Statistically significant differences on angina episodes assessed by Seattle Angina Questionnaire (min - 19, max - 108 better outcome), as compared to controls

Statistically significant differences according to the quality of life of patients assessed by Minnesota Questionnaire (min -0, max-105, worse outcome), as compared to controls

Statistically significant differences according to the quality of life of patients assessed by Clinical Assessment Scale for CHF(min -0, max-20, worse outcome), as compared to controls

Statistically significant differences of patients wellbeing according to the analog-visual scale , as compared to controls

ventricular fibrillation/triglyceride

Assessment of the Effects of Long-term Lipid-lowering Therapy in Patients With Primary STEMI or NSTEMI

PIoglitazone for PrEvention of Restenosis in Diabetic Patients

کاملترین پایگاه داده گیاهان دارویی با پشتیبانی علمی